Implementation of buffy‐coat‐derived pooled platelet concentrates for internal quality control of light transmission aggregometry: a proof of concept study

Abstract

Background Standardized commercially available control material for internal quality control (IQC) of light transmission aggregometry (LTA) is still lacking. Moreover, the availability of normal blood donors to provide fresh platelets is difficult in small laboratories, where 'volunteers' may be in short supply. Objectives To evaluate the implementation of buffy-coat-derived pooled platelet concentrates (PCs) for IQC material for LTA. Methods We used buffy-coat-derived pooled PCs from the blood bank as IQC material for LTA. On each weekend one PC was prepared (> 200 mL) and aliquoted from the original storage bag on a daily basis in four baby bags (40-50 mL), which were delivered from Monday to Friday to our laboratory. The IQC measurements of at least 85 work-weeks (from Monday to Friday) were evaluated with this new IQC material. LTA was performed on a four-channel Chronolog 700 Aggregometer (Chronolog Corporation, Havertown, PA, USA) (agonists: collagen, adenosine diphosphate [ADP], arachidonic acid [AA] and thrombin receptor activator peptide-6 [TRAP-6]). Results The medians of platelet aggregation from IQC measurements with collagen, ADP and AA from Monday to Friday were 68.0-59.5, 3.0-2.0 and 51.0-50.0%, respectively, and the mean of platelet aggregation with TRAP-6 was 71.2-66.4%. Conclusions Buffy-coat-derived pooled PCs serve as a reliable and robust IQC material for LTA measurements and would be beneficial for the whole laboratory procedure and employees' safety.

Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study

“…Light transmission aggregometry (LTA) was performed on a Chronolog 700 Lumi‐Aggregometer (Chronolog Corp, Havertown, Pennsylvania) using standard agonists of platelet aggregation (Collagen, ADP, arachidonic acid, TRAP) in order to stimulate platelet aggregation in platelet‐rich plasma …”

Classic Light Transmission Platelet Aggregometry: Do We Still Need it?

“…As such, there is scientific controversy concerning the use of PRP versus whole blood, 35 the impact of anticoagulants (e.g., DOACs interfere with thrombin-dependent platelet function, 36 but these effects are often overlooked because exogenous thrombin 36 is added in excess in most LTA protocols, as well as the influence of unfractionated heparin 37 ), centrifugation, transportation, 38 hands-on or turnaround time, 39 comparability between centers, adjusting platelet count, 40 41 standardization of used agonist, and quality control policies. 42 43 44 Moreover, the lowest reliable platelet count ranges from 30,000 to 100,000/μL, 45 46 which limits the analysis in patients with thrombocytopenia, a condition often found in IPD patients. Efforts to address and harmonize these issues have been made in published guidelines.…”

Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study

“…In parallel, blood was assayed on a chronology 700 Lumi-Aggregometer (Chrono-log Corp., Havertown, Pennsylvania, United States), a Multiplate analyzer (Roche Diagnostics GmbH, Vienna, Austria), and an Innovance PFA 2Y (Siemens Healthcare, Marburg, Germany) for determination of platelet counts, aggregation, and platelet function as previously described. 22…”